

Disclosure of movement of 1% or more in substantial holding  
or change in nature of relevant interest, or both

*Sections 277 and 278, Financial Markets Conduct Act 2013*

**To** NZX Limited

and

**To** Finzsoft Solutions Limited ("**Finzsoft**")

Relevant event being disclosed:	Change in nature of relevant interest and movement of 1% or more in substantial holding
Date of relevant event:	30 March 2015
Date this disclosure made:	31 March 2015
Date last disclosure made:	26 March 2015

**Substantial product holder(s) giving disclosure**

Full name:	Silverlake HGH Limited (" <b>Silverlake HGH</b> ")
------------	--

**Summary of substantial holding**

Class of quoted voting products:	Ordinary shares in Finzsoft (NZX:FIN)
Summary for:	Silverlake HGH

For **this** disclosure,—

(a) total number held in class:	7,528,990
(b) total in class:	8,566,164
(c) total percentage held in class:	87.892%

For **last** disclosure,—

(a) total number held in class:	6,622,940
(b) total in class:	8,566,164
(c) total percentage held in class:	77.315%

### Details of transactions and events giving rise to relevant event

On 27 February 2015, Silverlake HGH made a full takeover offer for all of the ordinary shares and other equity securities in Finzsoft (the “Offer”). The Offer price for the ordinary shares in Finzsoft is \$3.00 per share. Under the Offer, legal and beneficial ownership to shares which are accepted into the Offer transfers to Silverlake HGH on payment for those shares. A copy of the Offer document was sent to NZX on 27 February 2015. The Offer closed at 11.59pm on 30 March 2015.

Since the last disclosure dated 26 March 2015, Silverlake HGH has received additional acceptances to the Offer for a further 906,050 ordinary shares in Finzsoft.

On 30 March 2015, Silverlake HGH purchased 12,221 ordinary shares in Finzsoft under the Offer, and therefore became the legal and beneficial owner of those 12,221 ordinary shares.

As at the time of this notice, Silverlake HGH has a relevant interest in 7,528,990 ordinary shares in Finzsoft (representing 87.892% of all of the ordinary shares in Finzsoft) as follows:

- 6,622,940 ordinary shares (representing 77.315% of all of the ordinary shares in Finzsoft), being shares which are legally and beneficially owned by Silverlake HGH; and
- 906,050 ordinary shares (representing 10.577% of all of the ordinary shares in Finzsoft), being shares for which Silverlake HGH has received acceptances to the Offer, but which have not yet been paid for under the Offer (“**Acceptance Shares**”).

### Details after relevant event

Details for:	Silverlake HGH
Nature of relevant interest(s):	Registered holder and beneficial owner of ordinary shares in Finzsoft
For that relevant interest,—	
(a) number held in class:	6,622,940
(b) percentage held in class:	77.315%
(c) current registered holder(s):	Silverlake HGH
(d) registered holder(s) once transfers are registered:	Not applicable

### Details after relevant event

Details for:	Silverlake HGH
Nature of relevant interest(s):	Power to control the acquisition of ordinary shares in Finzsoft, on payment of the Offer price for those shares
For that relevant interest,—	
(a) number held in class:	906,050
(b) percentage held in class:	10.577%
(c) current registered holder(s):	Various

(d) registered holder(s) once transfers are registered: Silverlake HGH

**Additional information**

Address of substantial product holder: 26-01/04, 143 Cecil Street, GB Building, Singapore 069542

Contact details: Kwong Yong Sin  
+603 7721 6118  
raymondkwong@silverlakeaxis.com

Name of any other person believed to have given, or believed to be required to give, a disclosure under the Financial Markets Conduct Act 2013 in relation to the financial products to which this disclosure relates:

- Rubik Financial Limited
- HGH (ICT Investments No. 2) Limited and Silverlake Axis Ltd. (in each case, on Silverlake HGH acquiring legal and beneficial title to the Acceptance Shares).

**Certification**

I, Nathanael William Starrenburg, certify that, to the best of my knowledge and belief, the information contained in this disclosure is correct and that I am duly authorised to make this disclosure by all persons for whom it is made.